Literature DB >> 24257427

Cytomegalovirus vaccines.

Michael A McVoy1.   

Abstract

An effective cytomegalovirus (CMV) vaccine could prevent the majority of birth defects caused by congenital CMV infections. Candidate vaccines in clinical evaluation include live attenuated, protein subunit, DNA, and viral-vectored approaches. Subunit approaches have focused on the CMV proteins pp65 and IE1 as important inducers of cytotoxic T cells and glycoprotein B (gB) as an important inducer of neutralizing antibodies. A vaccine comprised of recombinant gB protein with MF59 adjuvant reduced the incidence of primary infection by 50%. Recent revelations regarding CMV entry pathways into different cell types suggest a possible course for improvement. A 5-subunit pentameric complex is uniquely required for endothelial and epithelial cell entry. Sera from naturally infected subjects contain high-potency neutralizing activities specific for this complex, whereas the gB/MF59 vaccine fails to induce comparable neutralizing activities. A vaccine's ability to induce salivary antibodies that neutralize epithelial cell entry may be especially important for preventing oral transmission as the first cells infected are presumably epithelial cells of the oral mucosa. In addition, recent evidence suggests that antibodies can inhibit postentry CMV spread between endothelial and epithelial cells. Such activities may serve to limit viral replication in tissues or impair dissemination to the placenta and fetus. Thus, inclusion of epitopes derived from the pentameric complex may provide enhanced efficacy by inducing potent neutralizing/spread-inhibiting antibodies that target virus replication in a broad spectrum of cell types. Next-generation vaccine candidates in preclinical development incorporate peptides, subunits, or multisubunit complexes representing parts or all of the pentameric complex. Approaches include peptides, recombinant proteins, DNA, replication-defective viral vectors, genetically disabled CMV, and inactivated CMV virions. The diversity of novel strategies under development engenders optimism that a successful candidate will emerge.

Entities:  

Keywords:  congenital infection; cytomegalovirus; vaccine

Mesh:

Substances:

Year:  2013        PMID: 24257427      PMCID: PMC3836572          DOI: 10.1093/cid/cit587

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  20 in total

1.  Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine.

Authors:  S E Frey; C Harrison; R F Pass; E Yang; D Boken; R E Sekulovich; S Percell; A E Izu; S Hirabayashi; R L Burke; A M Duliège
Journal:  J Infect Dis       Date:  1999-11       Impact factor: 5.226

2.  Genetic content of wild-type human cytomegalovirus.

Authors:  Aidan Dolan; Charles Cunningham; Ralph D Hector; Aycan F Hassan-Walker; Lydia Lee; Clare Addison; Derrick J Dargan; Duncan J McGeoch; Derek Gatherer; Vincent C Emery; Paul D Griffiths; Christian Sinzger; Brian P McSharry; Gavin W G Wilkinson; Andrew J Davison
Journal:  J Gen Virol       Date:  2004-05       Impact factor: 3.891

3.  Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus.

Authors:  Elizabeth A Reap; John Morris; Sergey A Dryga; Maureen Maughan; Todd Talarico; Robert E Esch; Sarah Negri; Bruce Burnett; Andrew Graham; Robert A Olmsted; Jeffrey D Chulay
Journal:  Vaccine       Date:  2007-08-30       Impact factor: 3.641

4.  The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL.

Authors:  M R Wills; A J Carmichael; K Mynard; X Jin; M P Weekes; B Plachter; J G Sissons
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

5.  Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response.

Authors:  M Urban; M Klein; W J Britt; E Hassfurther; M Mach
Journal:  J Gen Virol       Date:  1996-07       Impact factor: 3.891

6.  Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism.

Authors:  Dai Wang; Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-30       Impact factor: 11.205

7.  Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response.

Authors:  Masako Shimamura; Michael Mach; William J Britt
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

8.  A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.

Authors:  Thomas C Heineman; Mark Schleiss; David I Bernstein; Richard R Spaete; Lihan Yan; Greg Duke; Mark Prichard; Zhaoti Wang; Qing Yan; Margaret A Sharp; Nicola Klein; Ann M Arvin; George Kemble
Journal:  J Infect Dis       Date:  2006-04-12       Impact factor: 5.226

9.  Antibody inhibition of human cytomegalovirus spread in epithelial cell cultures.

Authors:  Xiaohong Cui; Ronzo Lee; Stuart P Adler; Michael A McVoy
Journal:  J Virol Methods       Date:  2013-05-10       Impact factor: 2.014

10.  Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age.

Authors:  S P Adler; S E Starr; S A Plotkin; S H Hempfling; J Buis; M L Manning; A M Best
Journal:  J Infect Dis       Date:  1995-01       Impact factor: 5.226

View more
  26 in total

1.  Vaccination with a Live Attenuated Cytomegalovirus Devoid of a Protein Kinase R Inhibitory Gene Results in Reduced Maternal Viremia and Improved Pregnancy Outcome in a Guinea Pig Congenital Infection Model.

Authors:  Mark R Schleiss; Craig J Bierle; Elizabeth C Swanson; Michael A McVoy; Jian Ben Wang; Zainab Al-Mahdi; Adam P Geballe
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

2.  Identification of a Continuous Neutralizing Epitope within UL128 of Human Cytomegalovirus.

Authors:  Flavia Chiuppesi; Teodora Kaltcheva; Zhuo Meng; Peter A Barry; Don J Diamond; Felix Wussow
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

Review 3.  Prospects of a vaccine for the prevention of congenital cytomegalovirus disease.

Authors:  Bodo Plachter
Journal:  Med Microbiol Immunol       Date:  2016-08-12       Impact factor: 3.402

4.  Dense Bodies of a gH/gL/UL128/UL130/UL131 Pentamer-Repaired Towne Strain of Human Cytomegalovirus Induce an Enhanced Neutralizing Antibody Response.

Authors:  Caroline Lehmann; Jessica Julia Falk; Nicole Büscher; Inessa Penner; Christine Zimmermann; Patricia Gogesch; Christian Sinzger; Bodo Plachter
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

5.  Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.

Authors:  Mark R Schleiss; Ursula Berka; Elizabeth Watson; Mario Aistleithner; Bettina Kiefmann; Bastien Mangeat; Elizabeth C Swanson; Peter A Gillis; Nelmary Hernandez-Alvarado; Claudia Fernández-Alarcón; Jason C Zabeli; Daniel D Pinschewer; Anders E Lilja; Michael Schwendinger; Farshad Guirakhoo; Thomas P Monath; Klaus K Orlinger
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

Review 6.  Non-conventional expression systems for the production of vaccine proteins and immunotherapeutic molecules.

Authors:  Isabelle Legastelois; Sophie Buffin; Isabelle Peubez; Charlotte Mignon; Régis Sodoyer; Bettina Werle
Journal:  Hum Vaccin Immunother       Date:  2016-12-01       Impact factor: 3.452

7.  Plasmablast Response to Primary Rhesus Cytomegalovirus (CMV) Infection in a Monkey Model of Congenital CMV Transmission.

Authors:  Qihua Fan; Cody S Nelson; Kristy M Bialas; Flavia Chiuppesi; Joshua Amos; Thaddeus C Gurley; Dawn Jones Marshall; Joshua Eudailey; Holly Heimsath; Jonathon Himes; Ashlesha Deshpande; Mark R Walter; Felix Wussow; Don J Diamond; Peter A Barry; M Anthony Moody; Amitinder Kaur; Sallie R Permar
Journal:  Clin Vaccine Immunol       Date:  2017-05-05

8.  Cytomegalovirus UL128 homolog mutants that form a pentameric complex produce virus with impaired epithelial and trophoblast cell tropism and altered pathogenicity in the guinea pig.

Authors:  Stewart Coleman; K Yeon Choi; Alistair McGregor
Journal:  Virology       Date:  2017-06-23       Impact factor: 3.616

9.  A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types.

Authors:  Lawrence M Kauvar; Keyi Liu; Minha Park; Neal DeChene; Robert Stephenson; Edgar Tenorio; Stote L Ellsworth; Takako Tabata; Matthew Petitt; Mitsuru Tsuge; June Fang-Hoover; Stuart P Adler; Xiaohong Cui; Michael A McVoy; Lenore Pereira
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

10.  Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.

Authors:  David I Bernstein; Flor M Munoz; S Todd Callahan; Richard Rupp; Susan H Wootton; Kathryn M Edwards; Christine B Turley; Lawrence R Stanberry; Shital M Patel; Monica M Mcneal; Sylvie Pichon; Cyrille Amegashie; Abbie R Bellamy
Journal:  Vaccine       Date:  2015-12-02       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.